- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT05292716
Mitral Regurgitation Treatment in Advanced Heart Failure (MITRADVANCE)
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
There are no studies comparing MitraClip and optimal medical therapy (OMT) in patients with advanced heart failure (HF).
The aim of this study is to assess the effects of MitraClip on health status, measured with the Kansas City Cardiomyopathy Questionnaire (KCCQ), in patients with secondary mitral regurgitation (SMR) and advanced HF.
Secondary aims are to evaluate persistence of such benefits up to 1 year as well as changes in survival, HF hospitalization, functional status, symptoms, echocardiographic parameters, and further optimization in medical therapies.
MITRADVANCE-HF is a prospective, randomized, parallel-controlled, open-label, multicenter study trial enrolling patients with SMR and advanced HF on maximally tolerated standard of care therapies for HF according to the most recent guidelines. Enrolled patients will be randomly assigned, in a 1:1 ratio, to a device arm consisting of MitraClip therapy added to optimal medical therapy (OMT) or a control arm of OMT alone. Primary end-point was the absolute change in overall KCCQ summary score (KCCQ-OS) from baseline to 3 months follow-up. A total of 172 patients should be recruited (86 in the device arm and 86 in the control arm. Approximately 20 Italian centers are involved. All screened patients need to be approved by an eligibility committee before randomization. Visit 0 will be performed before randomization. A discharge visit will be performed in patients randomized to the device arm. Visit 1, 2 and 3 will be performed at 3, 6 and 12 months after the randomization in both arms. Transthoracic echocardiography performed during Visit 0, 1, 2 and 3 will be collected and analyzed by an independent Core Laboratory. Adverse events will be adjudicated by an independent committee. Enrolment duration will be of 24 months. The primary completion is the date when the last enrolled subject is assessed for the collection of the primary endpoint. The end of the study is when the last enrolled subject has completed the last follow-up visit.
Study Type
Enrollment (Anticipated)
Phase
- Not Applicable
Contacts and Locations
Study Locations
-
-
Lombardy
-
Brescia, Lombardy, Italy, 25123
- Recruiting
- Marianna Adamo
-
Contact:
- Marianna Adamo, MD
- Phone Number: +393897834503
- Email: mariannaadamo@hotmail.com
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Age between 18 and 90 years
- Significant secondary mitral regurgitation (effective regurgitant orifice area ≥ 30mm2) confirmed at the end of the screening period
- Optimal medical therapy (OMT) according to recent guidelines.
Advanced heart failure defined as the presence of all the following criteria, despite OMT:
- Severe and persistent symptoms of HF (NYHA class III or IV)
- Severe cardiac dysfunction defined by a reduced LVEF ≤35% and/or high BNP or NTproBNP levels (BNP>125 pg/ml or NTproBNP>400 pg/ml if sinus rhythm; BNP>375 pg/ml or NTproBNP>1200 pg/ml if atrial fibrillation)
- At least 1 unplanned visit or hospitalization in the last 12 months, due to HF, and requiring intravenous diuretics and/or inotropes
- Severe impairment of quality of life (KCCQ < 75 points)
- Severe impairment of exercise capacity with inability to exercise or low 6MWT distance (<300 meters) or pVO2 (<12-14 mL/kg/min or <50% of predicted)
Exclusion Criteria:
- Unfavorable mitral valve anatomy, which implanting investigator judges as not successfully treatable by the MitraClip
- Echocardiographic evidence of intracardiac mass, thrombus or vegetation
- Active endocarditis or active rheumatic heart disease or leaflets degenerated from rheumatic disease (i.e., noncompliant, perforated)
- Active infections requiring current antibiotic therapy
- Transesophageal echocardiography (TEE) contraindicated or at high risk
- Untreated significant coronary artery disease requiring revascularization
- Iron deficiency defined as serum ferritin <100 μg/L, or ferritin between 100-299 μg/L and transferrin saturation <20% and/or intravenous ferric carboxymaltose administration during the 30 days before randomization
- Coronary artery bypass graft, percutaneous coronary intervention, transcatheter aortic valve replacement or cardiac resynchronization therapy within the prior 30 days
- Myocardial infarction or cerebrovascular accident within prior 30 days
- Hemodynamic instability defined as systolic blood pressure < 90mmHg and cardiogenic shock or need for inotropic support or intra-aortic balloon pump or other hemodynamic support device.
- Chronic obstructive pulmonary disease, malignancy, or other comorbidities as the main cause of severe symptoms and impaired quality of life.
- Life expectancy <12 months due to non-cardiac conditions
Study Plan
How is the study designed?
Design Details
- Primary Purpose: OTHER
- Allocation: RANDOMIZED
- Interventional Model: PARALLEL
- Masking: NONE
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
EXPERIMENTAL: MitraClip + Optimal medical therapy
Patients randomized to this arm will receive percutaneous treatment of secondary mitral regurgitation by MitraClip system and Optimal medical therapy (OMT) for heart failure
|
MitraClip
|
NO_INTERVENTION: Optimal medical therapy
Patients randomized to this arm will receive only Optimal medical therapy (OMT) for heart failure
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Absolute change in overall KCCQ summary score (KCCQ-OS)
Time Frame: from baseline to 3 months
|
Kansas City Cardiomyopathy Questionnaire (KCCQ) aims at evaluating quality of life in heart failure patients using a scale including 100 points (from 0 [worst] to 100 [best])
|
from baseline to 3 months
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Composite of all-cause death or unplanned HF hospitalization or change in KCCQ-OS
Time Frame: from baseline to 3, 6 and 12 months
|
Unplanned HF hospitalization is defined as Admission to an inpatient unit or ward in the hospital for ≥24 h, including an emergency department stay with symptoms, signs and/or laboratory evidence of worsening heart failure; pulmonary edema, administration of intravenous therapies (loop diuretic agents, vasodilators, inotropic agents, vasopressors) or mechanical heart failure therapies (ultrafiltration, cardiac resynchronization, IABP, LVAD); hospitalizations requiring oxygen therapy. Kansas City Cardiomyopathy Questionnaire (KCCQ) aims at evaluating quality of life in heart failure patients using a scale including 100 points (from 0 [worst] to 100 [best]). |
from baseline to 3, 6 and 12 months
|
All-cause death
Time Frame: at 3 months, 6 and 12 months
|
at 3 months, 6 and 12 months
|
|
Cardiovascular death
Time Frame: at 3 months, 6 and 12 months
|
Defined according to MVARC-2 definition as death due to Heart Failure, Myocardial Infarction, Major/Disabling Bleeding, Tromboembolism, Stroke, Arrythmia, Cardiovascular Infection, Cardiac Tamponade, Sudden Death, Device Failure
|
at 3 months, 6 and 12 months
|
Unplanned HF hospitalization
Time Frame: at 3, 6 and 12 months
|
Admission to an inpatient unit or ward in the hospital for ≥24 h, including an emergency department stay with symptoms, signs and/or laboratory evidence of worsening heart failure; pulmonary edema, administration of intravenous therapies (loop diuretic agents, vasodilators, inotropic agents, vasopressors) or mechanical heart failure therapies (ultrafiltration, cardiac resynchronization, IABP, LVAD); hospitalizations requiring oxygen therapy.
|
at 3, 6 and 12 months
|
Absolute change in KCCQ-OS
Time Frame: from baseline to 6 and 12 months
|
Kansas City Cardiomyopathy Questionnaire aims at evaluating quality of life in heart failure patients using a scale including 100 points (from 0 [worst] to 100 [best])
|
from baseline to 6 and 12 months
|
Other Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Absolute change in EQ-5D
Time Frame: from baseline to 3, 6 and 12 months
|
The EQ-5D questionnaire is standardized instrument for measuring generic health status using five dimensions.
Each dimension has 5 levels.
The final number is icluded between 0 and 1 (0=worst and 1=best)
|
from baseline to 3, 6 and 12 months
|
Patients' Global Impression of Change (PGIC) Scale
Time Frame: at 3, 6 and 12 months
|
The Patients' Global Impression of Change (PGIC) Scale will assess the degree of change in patient's health status in terms of overall improvement (very much improved, much improved, minimally improved, unchanged, minimally worse, much worse, very much worse.
|
at 3, 6 and 12 months
|
Change in NYHA class
Time Frame: from baseline to 3, 6 and 12 months
|
The New York Heart Association scale include 4 level of heart failure symptoms: 1=No limitation of physical activity, ordinary physical activity does not cause undue fatigue or dyspnea; 2= Slight limitation of physical activity, ordinary physical activity results in fatigue or dyspnea; 3: Marked limitation of physical activity, less than ordinary activity causes fatigue or dyspnea; 4=Symptoms of heart failure at rest
|
from baseline to 3, 6 and 12 months
|
Absolute and percentage change in 6-minute walk test (6MWT) distance in meters
Time Frame: from baseline to 3, 6 and 12 months
|
from baseline to 3, 6 and 12 months
|
|
Absolute change and percentage in NT-proBNP levels in pg/mL
Time Frame: from baseline to 3, 6 and 12 months.
|
from baseline to 3, 6 and 12 months.
|
|
Absolute and percentage change in systolic pulmonary pressure (mmHg) assessed by echocardiography
Time Frame: from baseline to 3, 6 and 12 months
|
from baseline to 3, 6 and 12 months
|
|
Absolute and percentage change in left atrial volume (mL)
Time Frame: from baseline to 3, 6 and 12 months.
|
from baseline to 3, 6 and 12 months.
|
|
Absolute and percentage change in left ventricular end-diastolic and end-systolic volumes (mL)
Time Frame: from baseline to 3, 6 and 12 months
|
from baseline to 3, 6 and 12 months
|
|
Absolute and percentage change in right ventricular fractional area change (FAC) (percent)
Time Frame: from baseline to 3, 6 and 12 months
|
from baseline to 3, 6 and 12 months
|
|
Absolute and percentage change in diuretic dose
Time Frame: from baseline to 3, 6 and 12 months
|
from baseline to 3, 6 and 12 months
|
Collaborators and Investigators
Study record dates
Study Major Dates
Study Start (ACTUAL)
Primary Completion (ANTICIPATED)
Study Completion (ANTICIPATED)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (ACTUAL)
Study Record Updates
Last Update Posted (ACTUAL)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- NP4918
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
product manufactured in and exported from the U.S.
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Heart Failure
-
Tufts Medical CenterMetro West Medical CenterCompletedCongestive Heart Failure | Diastolic Heart Failure | Systolic Heart FailureUnited States
-
Abbott Medical DevicesCompletedHeart Failure | Heart Failure, Diastolic | Heart Failure, Systolic | Heart Failure NYHA Class II | Heart Failure NYHA Class III | Heart Failure With Reduced Ejection Fraction | Heart Failure NYHA Class IV | Heart Failure With Normal Ejection Fraction | Heart Failure; With Decompensation | Heart Failure...United States, Canada
-
Manipal UniversityUnknownHeart Failure | Decompensated Heart Failure | Acute Heart Failure | Diastolic Heart Failure | Systolic Heart FailureIndia
-
University Hospital, MontpellierCompletedHeart Failure | Diastolic Heart Failure | Systolic Heart Failure Stage CFrance
-
VA Eastern Colorado Health Care SystemNational Institute on Aging (NIA)CompletedHeart Failure | Heart Failure, Diastolic | Heart Failure, Systolic | Heart Failure With Reduced Ejection Fraction | Heart Failure With Preserved Ejection Fraction | Heart Failure; With Decompensation | Heart Failure,Congestive | Heart Failure AcuteUnited States
-
Wake Forest UniversityCompletedHeart Failure, Congestive | Heart Failure With Preserved Ejection Fraction
-
Lancaster General HospitalLouise von Hess Medical Research InstituteEnrolling by invitationDiastolic Heart FailureUnited States
-
Wake Forest UniversityNational Institute on Aging (NIA)CompletedHeart Failure, Congestive | Diastolic Heart FailureUnited States
-
Giresun UniversityIstanbul University - Cerrahpasa (IUC)RecruitingHeart Failure | Diastolic Heart Failure | Systolic Heart FailureTurkey
-
US Department of Veterans AffairsCompleted
Clinical Trials on MitraClip
-
Abbott Medical DevicesCompletedMitral Regurgitation | Mitral Valve Insufficiency | Mitral Valve Regurgitation | Mitral Valve Incompetence | Mitral InsufficiencyUnited States
-
Population Health Research InstituteCompletedMitral RegurgitationCanada
-
Abbott Medical DevicesActive, not recruitingHeart Failure | Mitral Regurgitation | Mitral Valve Regurgitation | Treatment of Functional Mitral Regurgitation in Symptomatic Heart Failure SubjectsUnited States, Canada
-
Nantes University HospitalAbbott; Ministère de la SantéRecruiting
-
Abbott Medical DevicesAbbottTerminated
-
Fundación Investigación Sanitaria en LeónAbbott Medical DevicesCompletedMitral Regurgitation | Acute Myocardial Infarction
-
Hospital Clinic of BarcelonaAbbottUnknownMITRAL REGURGITATIONSpain
-
Queen's UniversityAFP Innovation FundRecruiting